Arrhythmias in hypertrophic cardiomyopathy

PACE - Pacing and Clinical Electrophysiology

Volumn 20, Issue 10 II, 1997, Pages 2706-2713

  Kuck, Karl Heinz ^a  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

Hypertrophic cardiomyopathy; Nonsustained ventricular tachycardia; PES; Risk stratification

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; PROPRANOLOL; VERAPAMIL;

CONFERENCE PAPER; DEFIBRILLATOR; ELECTROCARDIOGRAM; ELECTROPHYSIOLOGY; ELECTROSTIMULATION; HEART ARRHYTHMIA; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; RISK ASSESSMENT; RISK FACTOR; SUDDEN DEATH; SYNCOPE;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY, AMBULATORY; HUMANS; RISK ASSESSMENT; RISK FACTORS; TACHYCARDIA, VENTRICULAR;

EID: 0030724161     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.1997.tb06120.x     Document Type: Article

References (67)

1. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy. Recent observations regarding the specificity of three hallmarks of the disease: Asymmetric septal hypertrophy, septal disorganization and systolic anterior motion of the anterior mitral leaflet. Am J Cardiol 1980; 45:141-154.
2. McKenna W, Deanfield J, Faruqui A, et al. Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981; 47:532-538.
3. Maron BJ, Roberts WC, Edwards JE, et al. Sudden death in patients with hypertrophic cardiomyopathy: Characterization of 26 patients with functional limitation. Am J Cardiol 1978; 41:803-810.
4. Goodwin JF, Krikler DM. Arrhythmia as a cause of sudden death in hypertrophic cardiomyopathy. Lancet 1976; 2:937-940.
5. Hardarson T, De la Calzada CS, Curiel R, et al. Prognosis and mortality of hypertrophic obstructive cardiomyopathy. Lancet 1973; 2:1462-1467.
6. Krelhaus W, Kuhn H, Loogen F. Analysis of deaths in the course of hypertrophic obstructive cardiomyopathy. In M Kaltenbach, F Loogen, EG Olson EG (eds.): Cardiomyopathy and Myocardial Biopsy. Berlin, Springer, 1978, pp. 1133-1139.
7. Brock R. Functional obstruction of the left ventricle (acquired aortic stenosis). Guys Hosp Rep 1957; 106:221-238.
8. Brugada P, Bär FW, de Zwaan G, et al. "Sawfish" systolic narrowing of the left anterior descending coronary artery: An angiographic sign of hypertrophic cardiomyopathy. Circulation 1982; 66:800-803.
9. Ruddy TD, Henderson MA, Radowski H, et al. Systolic constriction of the coronary arteries in hypertrophic cardiomyopathy. (abstract) Circulation 1981; 64(Suppl. IV):IV-239.
10. Maron BJ, Wolfson JK, Epstein SE, et al. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986; 8:545-557.
11. Maron BJ, Epstein SE, Roberts WC. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol 1979; 43:1086-1102.
12. Chmielewski CA, Riley RS, Mahendran A, et al. Complete heart block as a cause of syncope in asymmetric septal hypertrophy. Am Heart J 1977; 93:91-93.
13. Joseph S, Balcon R, McDonald L. Syncope in hypertrophic obstructive cardiomyopathy due to asystole. Br Heart J 1972; 34:974-976.
14. Krikler DM, Davies MJ, Rowland E, et al. Sudden death in hypertrophic cardiomyopathy: Associated accessory atrioventricular pathways. Br Heart J 1980; 43:245-251.
15. Wellens HJ, Bär FW, Vanagt EJ. Death after ajmaline administration. (letter) Am J Cardiol 1980; 45:905.
16. McKenna WJ, Chetty S, Oakley CM, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy: Exercise and 48 hour ambulatory electrocardiographic assessment with and without beta adrenergic blocking therapy. Am J Cardiol 1980; 45:1-5.
17. McKenna WJ, England D, Doi YL, et al. Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br Heart J 1981; 46:168-172.
18. Maron BJ, Savage DD, Wolfson JK, et al. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: A prospective study. Am J Cardiol 1981; 48:252-257.
19. Savage DD, Seides SF, Maron BJ, et al. Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation 1979; 59:866-875.
20. Kuck KH, Hanrath P, Kunze KP, et al. Programmed electrical stimulation in hypertrophic cardiomyopathy - identification of patients at risk for sudden death. (abstract) Eur Heart J 1983; 4 (Suppl. E):7.
21. Glancy DL, O'Brien KP, Gold HK, et al. Atrial fibrillation in patients with idiopathic hypertrophic subaortic stenosis. Br Heart J 1970; 32:652-659.
22. Henry WL, Morganroth J, Pearlman AS, et al. Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation 1976; 53:273-279.
23. Watson DC, Henry WL, Epstein SE, et al. Effects of operation on left atrial size and the occurrence of atrial fibrillation in patients with hypertrophic subaortic stenosis. Circulation 1977; 55:178-181.
24. Gilbert BW, Pollick C, Adelman AG, et al. Hypertrophic cardiomyopathy: Subclassification by M mode echocardiography. Am J Cardiol 1980; 45:861-872.
25. McKenna WJ, Goodwin JF. The natural history of hypertrophic cardiomyopathy. Curr Probl Cardiol 1981; 6:1-26.
26. Robinson K, Frenneaux MP, Stockins B, et al. Atrial fibrillation in hypertrophic cardiomyopathy: A longitudinal study. J Am Coll Cardiol 1990; 15:1279-1285.
27. Fananapazir L, Chang AC, Epstein SE, et al. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation 1992; 86:730-740.
28. Atiga WL, McAreavey D, Epstein ND, et al. Risk stratification of asymptomatic patients with hypertrophic cardiomyopathy. (abstract) J Am Coll Cardiol 1994; 23:110A.
29. Spirito P, Rapezzi C, Autore C, et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994; 90:2743-2747.
30. Fananapazir L, Tracy CM, Leon MB, et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation 1989; 80:1259-1268.
31. Fananapazir L, Epstein SE. Hemodynamic and electrophysiologic evaluation of patients with hypertrophic cardiomyopathy surviving cardiac arrest. Am J Cardiol 1991; 67:280-287.
32. Ruddy TD, Henderson MA, Downar E, et al. Ventricular tachycardia and degree of left ventricular hypertrophy in hypertrophic cardiomyopathy. (abstract) Circulation 1982; 66(Suppl. II):II-343.
33. McKenna WJ, Deanfield J, Franklin R, et al. Arrhythmia in children and adolescents with hypertrophic cardiomyopathy: Incidence and relation to prognosis. (abstract) J Am Coll Cardiol 1986; 7:204A.
34. Maron BJ, Henry-WL, Clark CE, et al. Asymmetric septal hypertrophy in childhood. Circulation 1976; 53:9-19.
35. McKenna W, Harris L, Deanfield J. Syncope in hypertrophic cardiomyopathy. Br Heart J 1982; 47:177-179.
36. Hamer A, Vohra J, Hunt D, et al. Prediction of sudden death by electrophysiologic studies in high risk patients surviving acute myocardial infarction. Am J Cardiol 1982; 50:223-229.
37. Mason JW, Winkle RA. Accuracy of the ventricular tachycardia-induction study for predicting long-term efficacy and inefficacy of antiarrhythmic drugs. N Engl J Med 1980; 303:1073-1077.
38. Richards DA, Cody DV, Denniss AR, et al. Ventricular electrical instability: A predictor of death after myocardial infarction. Am J Cardiol 1983; 51:75-80.
39. Ruskin JN, DiMarco JP, Garan H. Out-of-hospital cardiac arrest: Electrophysiologic observations and selection of long-term antiarrhythmic therapy. N Engl J Med 1980; 303:607-613.
40. Anderson KP, Stinson EB, Derby GC, et al. Vulnerability of patients with obstructive hypertrophic cardiomyopathy to ventricular arrhythmia induction in the operating room: Analysis of 17 patients. Am J Cardiol 1983; 51:811-816.
41. Kowey PR, Eisenberg R, Engel TR. Sustained arrhythmias in hypertrophic obstructive cardiomyopathy. N Engl J Med 1984; 310:1566-1569.
42. Borggrefe M, Breithardt G. Programmierte Kammerstimulation bei Patienten mit hypertrophischer Kardiomyopathie. (abstract) Z Kardiol 1985; 74(Suppl. 5):52.
43. Geibel A, Brugada P, Zehender M, et al. Value of programmed electrical stimulation using a standardized ventricular stimulation protocol in hypertrophic cardiomyopathy. Am J Cardiol 1987; 60:738-739.
44. Kuck KH, Kunze KP, Schlüter M, et al. Programmed electrical stimulation in patients with hypertrophic cardiomyopathy. Results in patients with and without cardiac arrest or syncope. Eur Heart J 1988; 9:177-185.
45. Brugada P, Abdollah H, Heddle B, et al. Results of a ventricular stimulation protocol using a maximum of 4 premature stimuli in patients without documented or suspected ventricular arrhythmias. Am J Cardiol 1983; 52:1214-1218.
46. Wellens HJ, Bär FW, Vanagt EJ, et al. Medical treatment of ventricular tachycardia: Considerations in the selection of patients for surgical treatment. Am J Cardiol 1982; 49:186-193.
47. Stafford WJ, Trohman RG, Bilsker M, et al. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. J Am Coll Cardiol 1986; 7:701-704.
48. Saumarez RC, Camm AJ, Panagos A, et al. Ventricular fibrillation in hypertrophic cardiomyopathy is associated with increased fractionation of paced right ventricular electrograms. Circulation 1992; 86:467-474.
49. Saumarez RC, Slade AK, Grace AA, et al. The significance of paced electrogram fractionation in hypertrophic cardiomyopathy. A prospective study. Circulation 1995; 91:2762-2768.
50. Cohen LS, Braunwald E. Chronic beta adrenergic receptor blockade in the treatment of idiopathic hypertrophic subaortic stenosis. Prog Cardiovasc Dis 1968; 11:211-221.
51. Kuhn H, Loogen F. Use of beta-receptor blockaders in hypertrophic obstructive cardiomyopathy. Internist (Berl) 1978; 19:527-531.
52. Kuck KH, Dernedde J, Geiger M, et al. Inefficacy and adverse effects of sotalol on arrhythmia in hypertrophic cardiomyopathy. (abstract) J Am Coll Cardiol 1985; 5:450.
53. Canedo MI, Frank MJ, Abdulla AM. Rhythm disturbances in hypertrophic cardiomyopathy: Prevalence, relation to symptoms and management. Am J Cardiol 1980; 45:848-855.
54. Kaltenbach M, Hopf R, Kober G, et al. Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J 1979; 42:35-42.
55. Kuhn H, Thelen K, Cluver C, et al. Long-term verapamil treatment in patients with hypertrophic cardiomyopathy. In M Kaltenbach, SE Epstein (eds.): Hypertrophic Cardiomyopathy. Berlin, Springer, 1982, pp. 214-219.
56. Epstein SE, Rosing DR. Verapamil: Its potential for causing serious complications in patients with hypertrophie cardiomyopathy. Circulation 1981; 64:437-441.
57. Cranefield PF, Aronson RS, Wit AL. Effect of verapamil on the normal action potential and on a calcium-dependent slow response of canine cardiac Purkinje fibers. Circ Res 1974; 34:204-213.
58. McKenna WJ, Harris L, Perez G, et al. Arrhythmia in hypertrophic cardiomyopathy. II: Comparison of amiodarone and verapamil in treatment. Br Heart J 1981; 46:173-178.
59. Kaltenbach M, Hopf R. Conservative medical treatment of hypertrophic myocardiopathies. Z Kardiol 1982; 71:795-805.
60. Borggrefe M, Kuhn H, Königer HH, et al. Arrhythmias in hypertrophic obstructive and non-obstructive cardiomyopathy. Eur Heart J 1983; 4(Suppl. F):245-251.
61. McKenna WJ, Harris L, Rowland E, et al. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. Am J Cardiol 1984; 54:802-810.
62. Kuck KH, Kunze KP, Dernedde J, et al. Amiodarone in hypertrophic cardiomyopathy-electrophysiologic and long-term electrocardiographic study and clinical follow-up. (abstract) Circulation 1985; 72(Suppl. III):III-168.
63. McKenna WJ, Oakley CM, Krikler DM, et al. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985; 53:412-416.
64. Sclarovsky S, Lewin RF, Kracoff O, et al. Amiodarone-induced polymorphous ventricular tachycardia. Am Heart J 1983; 105:6-12.
65. Fananapazir L, Leon MB, Bonow RO, et al. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol 1991; 67:169-174.
66. Fananapazir L, Epstein SE. Value of electrophysiologic studies in hypertrophic cardiomyopathy treated with amiodarone. Am J Cardiol 1991; 67:175-182.
67. Kuck KH, Cappato R, Siebels J. ICD Therapy (Clinical Approaches To Tachyarrhythmias, Vol. 5). Armonk, New York, Futura Publishing Company, Inc., 1996.